These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8015075)

  • 21. Intravesical therapy of bladder cancer: an immunotherapy success story.
    Morales A
    Int J Urol; 1996 Sep; 3(5):329-33. PubMed ID: 8886906
    [No Abstract]   [Full Text] [Related]  

  • 22. Superficial bladder disease: case studies and therapeutic advances.
    Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
    Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
    [No Abstract]   [Full Text] [Related]  

  • 23. Diagnosis and treatment of superficial bladder cancer: an update.
    Crawford ED
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):1-9. PubMed ID: 8727804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder.
    Konety BR; Williams RD
    BJU Int; 2004 Jul; 94(1):18-21. PubMed ID: 15217424
    [No Abstract]   [Full Text] [Related]  

  • 26. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Standards and perspectives in diagnosis and therapy of bladder carcinoma].
    Stief C; Zaak D; Stöckle M; Studer U; Knuechel R; Rödel C; Sauer R; Rubben H
    Urologe A; 2006 Sep; 45 Suppl 4():90-6. PubMed ID: 16896761
    [No Abstract]   [Full Text] [Related]  

  • 28. Hypersensitivity pneumonitis as a complication of intravesical BCG therapy for bladder cancer.
    Carrasco Hernández L; Castaño Núñez ÁL; Rodríguez Portal JA
    Arch Bronconeumol; 2016 Aug; 52(8):445-6. PubMed ID: 26920491
    [No Abstract]   [Full Text] [Related]  

  • 29. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy.
    Draga RO; Grimbergen MC; Kok ET; Jonges TN; van Swol CF; Bosch JL
    Eur Urol; 2010 Apr; 57(4):655-60. PubMed ID: 19819064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S
    Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
    [No Abstract]   [Full Text] [Related]  

  • 31. The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer.
    Brosman SA; Lamm DL
    J Urol; 1990 Aug; 144(2 Pt 1):313-5. PubMed ID: 2374197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing superficial bladder cancer: an overview.
    Soloway MS
    Urology; 1992 Dec; 40(6 Suppl):5-10. PubMed ID: 1466119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary disease following intravesical BCG treatment.
    Kesten S; Title L; Mullen B; Grossman R
    Thorax; 1990 Sep; 45(9):709-10. PubMed ID: 2218978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis and treatment of octogenarian neoplastic patients: bladder cancers].
    Destefanis P; Bisconti A; Lasaponara F; Fontana D
    Urologia; 2010; 77 Suppl 17():32-7. PubMed ID: 21308672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical experience with BCG immune prevention in superficial bladder cancer].
    Bach D; Romics I; Rüssel C
    Urologe A; 1992 Sep; 31(5):296-301. PubMed ID: 1302409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravesical chemotherapy.
    Prout GR
    Prog Clin Biol Res; 1984; 162B():125-50. PubMed ID: 6438639
    [No Abstract]   [Full Text] [Related]  

  • 38. Bladder carcinoma--the good, the bad and the ugly.
    Manyak MJ
    J Urol; 1996 Jan; 155(1):103-4. PubMed ID: 7490802
    [No Abstract]   [Full Text] [Related]  

  • 39. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
    Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
    Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyarthritis in an elderly man with bladder cancer.
    Varoqua S; Lin-Greenberg A; Brown M
    Hosp Pract (Off Ed); 1994 Jun; 29(6):75, 78. PubMed ID: 8207112
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.